沐舒坦经超声电导透皮给药治疗小儿支气管肺炎的疗效分析

目的探讨沐舒坦经超声电导透皮给药对小儿支气管肺炎的治疗效果。方法选取小儿支气管肺炎患儿105例随机分为A、B、C三组，每组35例。A组患者沐舒坦注射液雾化吸入给药，B组患者超声电导透皮给药，C组患者静脉推注给药。比较三组的发热、咳嗽、喘憋、肺部哮鸣音消失时间、平均住院时间及治疗效果。结果B组的有效率明显高于A、C组，差异有统计学意义（P〈0．05）；三组的临床症状及平均住院时间比较，差异有统计学意义（P〈0．05），其中B组发热、咳嗽、喘憋、肺部哮鸣音消失时间及平均住院时间明显短于A、C两组（19〈0．05）。结论沐舒坦采用超声电导透皮给药方式治疗小儿支气管肺炎能够明显缩短患儿的病程，且不良反应少，可以作为一种治疗新途径在临床推广应用。

The Efficacy of Ambroxol Transdermal Delivery by Ultrasound Conductivity in Children with Bronchial Pneumonia

Objective To explore the efficacy of ambroxol transdermal delivery by ultrasound conductivity in children with bronchial pneumonia. Methods All 105 children with bronchopneumonia were selected and randomly divided into Group A treated with aerosol inhalation of ambroxol injection, Group B treated with ultrasonic electric conductivity percutaneous of the same drug and Group C treated with injection administration with 35 cases in each group. The difference of vanishing time of fever, cough, asthmatic, wheezes, the average hospital stay and therapeutic effect were compared in the three groups. Results The therapeutic effect in group B was much higher than that in the other groups with a significant difference （ P 〈 0.05 ）. There was a significant difference in symptom and average hospital stay of three groups （P ~ 0.05 ）. Compared with Group A and Group C, the vanishing time of fever, cough, asthmatic, wheezes, the average hospital stay in Group B were much shorter （P 〈 0.05 ）. Conclusion Ambroxol transdermal delivery by ultrasound conductivity in children with bronchial pneumonia could shorten the duration of symptoms and show less adverse reactions. It could be a new approach for treatment and worthy of clinical application.